The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy
Liangliang Wu(Beijing Institute of Aeronautical Materials), Shunchang Jiao(Chinese PLA General Hospital), Guoqing Zhang(Chinese PLA General Hospital), Jinfeng Li(Hebei Medical University), Tianyi Liu(Chinese PLA General Hospital), Wenjuan Gao(Chinese PLA General Hospital), Shengzhi Xie(Chinese PLA General Hospital), Lu Han(Songjiang District Central Hospital), Qiyan Wu(Chinese PLA General Hospital), Boyu Qin(Chinese PLA General Hospital), Lingxiong Wang(Chinese PLA General Hospital), Lijun Zhang(Dalian Medical University), Huafeng Wei(Ministry of Education of the People's Republic of China)
Cited by 21
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
|Clinical Cancer Research|2014|350
Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients
|Clinical Cancer Research|2017|272
Triazole–Dithiocarbamate Based Selective Lysine Specific Demethylase 1 (LSD1) Inactivators Inhibit Gastric Cancer Cell Growth, Invasion, and Migration
|Journal of Medicinal Chemistry|2013|221
Expression of ER-α36, a Novel Variant of Estrogen Receptor α, and Resistance to Tamoxifen Treatment in Breast Cancer
|Journal of Clinical Oncology|2009|218